Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients

Biomark Med. 2018 Oct;12(10):1125-1138. doi: 10.2217/bmm-2018-0069. Epub 2018 Sep 7.

Abstract

Aim: We assessed an autoantibody against new gene expressed in prostate (NGEP) protein for prostate cancer (PCa) that may better diagnosis and prognosis approaches in the patients with PCa.

Methods: Autoantibodies against NGEP were measured in sera of PCa patients by ELISA.

Results: The autoantibody against NGEP is present in a significantly higher proportion in the sera of PCa patients as compared with healthy controls (p < 0.001). An inverse significant correlation was found between seropositive patients and Gleason score (p < 0.05) and serum prostate-specific antigen (recombinant NGEP; p < 0.05).

Conclusion: The data showed that measurement of autoantibody against NGEP as a novel prostate-specific antigen in sera can be used as a potential biomarker to discriminate well-differentiated PCa patients from normal subjects.

Keywords: ELISA; Gleason score; NGEP; PSA level; autoantibody; biomarker; prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anoctamins / genetics
  • Anoctamins / immunology*
  • Anoctamins / metabolism
  • Area Under Curve
  • Autoantibodies / blood*
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • ROC Curve
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / immunology
  • Recombinant Proteins / isolation & purification
  • Sensitivity and Specificity

Substances

  • ANO7 protein, human
  • Anoctamins
  • Autoantibodies
  • Recombinant Proteins
  • Prostate-Specific Antigen